688091 Shanghai Yizhong Pharmaceutical
- 42.71
- -0.26-0.61%
Shanghai Yizhong Pharmaceutical News
Announcement of Shanghai Yizhong Pharmaceutical Co., Ltd. on adjusting the upper limit of share repurchase prices and extending the implementation period
Announcement of the progress of Shanghai Yizhong Pharmaceutical Co., Ltd. on the repurchase of the company\'s shares through centralized bidding transactions
Announcement of the progress of Shanghai Yizhong Pharmaceutical Co., Ltd. on the repurchase of the company\'s shares through centralized bidding transactions
Announcement of the progress of Shanghai Yizhong Pharmaceutical Co., Ltd. on the repurchase of the company\'s shares through centralized bidding transactions
Announcement on the initial public offering of some restricted shares of Shanghai Yizhong Pharmaceutical Co., Ltd.
Announcement of Shanghai Yizhong Pharmaceutical Co., Ltd. on the first repurchase of the company\'s shares through centralized bidding
Repurchase Report of Shanghai Yizhong Pharmaceutical Co., Ltd. on the repurchase of shares through centralized bidding
Plan of Shanghai Yizhong Pharmaceutical Co., Ltd. to repurchase shares by means of centralized bidding
Legal opinion of Shanghai Jintiancheng Law Firm on the adjustment of Shanghai Yizhong Pharmaceutical Co., Ltd.'s 2022 restricted stock incentive plan
Announcement on Adjusting Relevant Matters of Restricted Stock Incentive Plan for 2022 by Shanghai Yizhong Pharmaceutical Co., Ltd.
Shanghai Yizhong Pharmaceutical Co., Ltd. 2023 Equity Distribution Implementation Notice
Announcement of Shanghai Yizhong Pharmaceutical Co., Ltd. on the 2023 profit distribution and capital reserve transfer plan
Announcement of Shanghai Yizhong Pharmaceutical Co., Ltd. on matters relating to the adjustment of the 2022 restricted stock incentive plan
Announcement of Shanghai Yizhong Pharmaceutical Co., Ltd. on meeting the eligibility requirements for the first vesting period of the 2022 Restricted Stock Incentive Plan
The supervisory board's review opinion on the list of incentive recipients
Legal Opinion of Shanghai AllBright Law Firm on matters relating to the first vesting period of the 2022 Restricted Stock Incentive Plan of Shanghai Yizhong Pharmaceutical Co., Ltd. meeting the conditions of ownership and the adjustment of the 2022 Restric
Announcement of Shanghai Yizhong Pharmaceutical Co., Ltd. holding 5% or more of the shareholders\' holdings and the expiration of the plan to reduce their holdings without reducing their holdings
Announcement on the results of the reduction of shareholdings by shareholders of Shanghai Yizhong Pharmaceutical Co., Ltd.
Announcement of Shanghai Yizhong Pharmaceutical Co., Ltd. on the unfreezing of company shares held by company shareholders
Announcement on the results of the reduction of shareholding by directors and senior managers of Shanghai Yizhong Pharmaceutical Co., Ltd.
Analysis
Price Target
No Data
No Data